{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:17:01Z","timestamp":1793254621553,"version":"4.5.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Human parvovirus B19 (HPV B19) is a single-stranded DNA virus. The detection rate of HPV B19 in the blood of healthy blood donors using PCR technology was reported to be 6.323\/100000. However, that among hospitalized patients suspected of being infected with a pathogenic microorganism is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was conducted on 2,182 high-throughput NGS results for 1,484 inpatients admitted to the First Affiliated Hospital of Zhengzhou University from January 2020 to October 2021 who were suspected of being infected with a pathogenic microorganism, as well as on clinical data of some HPV B19-positive patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Human parvovirus B19 was detected in 39 samples from 33 patients. The positivity rate was 2.22% among patients and 1.78% among samples. HPV B19 was detected in 20 cerebrospinal fluid samples, 13 blood samples, 3 alveolar lavage fluid samples, 2 tissue samples, and 1 throat swab. Based on clinical symptoms and NGS results, 16 patients were diagnosed with HPV B19 infection. The number of HPV B19 sequences in these patients was greater than 6, and the patients showed common symptoms such as fever (14 cases), anemia (11 cases), and severe nervous system symptoms such as meningoencephalitis (9 cases) and Guillain\u2013Barr\u00e9 syndrome with peripheral motor and sensory nerve axon damage (4 cases). All 16 patients had experienced events likely to lead to decreased immunity (11 had a history of trauma\/surgery\/major disease, 4 had a history of precursor infection, and 3 had used immunosuppressants) and 7 had a history of blood transfusion during hospitalization. After treatment with antiviral drugs (12 cases) and intravenous human immunoglobulin (3 cases), of the 16 patients, 14 patients improved.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The HPV B19 infection rate in hospitalized patients suspected of microbial infection was 2.22%. Most patients with HPV B19 infection had a history of low immunity and blood transfusion. HPV B19 could be detected in various bodily fluids and tissues (especially cerebrospinal fluid) using NGS. Patients with severe HPV B19 infection may have nervous system damage such as Guillain\u2013Barr\u00e9 syndrome and meningoencephalitis. Early diagnosis using NGS and treatment with antiviral drugs and immunoglobulin can improve prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2022.1083839","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:28:06Z","timestamp":1671622086000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Human parvovirus B19 infection in hospitalized patients suspected of infection with pathogenic microorganism"],"prefix":"10.3389","volume":"12","author":[{"given":"Junshuang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41590-021-01117-7","article-title":"IFN\u03b3 and GM-CSF control complementary differentiation programs in the monocyte-to-phagocyte transition during neuroinflammation","volume":"23","author":"Amorim","year":"2022","journal-title":"Nat. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/rmv.388","article-title":"Neurological manifestations of human parvovirus B19 infection","volume":"13","author":"Barah","year":"2003","journal-title":"Rev. Med. Virol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/rmv.1782","article-title":"Neurological aspects of human parvovirus B19 infection: A systematic review","volume":"24","author":"Barah","year":"2014","journal-title":"Rev. Med. Virol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1126\/science.8211117","article-title":"Erythrocyte p antigen: cellular receptor for B19 parvovirus","volume":"262","author":"Brown","year":"1993","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s13365-020-00885-6","article-title":"Acute viral encephalitis associated with human parvovirus B19 infection: unexpectedly diagnosed by metagenomic next-generation sequencing","volume":"26","author":"Cao","year":"2020","journal-title":"J. Neurovirol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/s0140-6736(75)91074-0","article-title":"Parvovirus-like particles in human sera","volume":"1","author":"Cossart","year":"1975","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1086\/599042","article-title":"Neurologic manifestations associated with parvovirus B19 infection","volume":"48","author":"Douvoyiannis","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1128\/cmr.15.3.485-505.2002","article-title":"Human parvovirus B19","volume":"15","author":"Heegaard","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12985-015-0396-z","article-title":"Prevalence of human parvovirus B19 in Chinese plasma pools for manufacturing plasma derivatives","volume":"12","author":"Jia","year":"2015","journal-title":"Virol. J."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104857","article-title":"A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19","volume":"180","author":"Jockusch","year":"2020","journal-title":"Antiviral Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1423-0410.2010.01423.x","article-title":"Epidemiology of high-level parvovirus B19 viraemia among Dutch blood donor -2009","volume":"100","author":"Kooistra","year":"2011","journal-title":"Vox Sang"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.711674","article-title":"The effect of a combined ganciclovir, methylprednisolone, and immunoglobulin regimen on survival and functional outcomes in patients with Japanese encephalitis","volume":"12","author":"Miao","year":"2021","journal-title":"Front. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s0163-4453(98)94531-5","article-title":"A case of Guillain-Barr\u00e9 syndrome associated with human parvovirus B19 infection","volume":"36","author":"Minohara","year":"1998","journal-title":"J. Infect."},{"key":"B14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/INF.0b013e3181694fcf","article-title":"Acute encephalopathy with human parvovirus B19 infection in hereditary spherocytosis","volume":"27","author":"Oshima","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.5409\/wjcp.v4.i4.126","article-title":"Acute encephalitis and encephalopathy associated with human parvovirus B19 infection in children","volume":"4","author":"Watanabe","year":"2015","journal-title":"World J. Clin. Pediatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/s0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 Syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1056\/NEJMra030840","article-title":"Parvovirus B19","volume":"350","author":"Young","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.807937","article-title":"Treatment of severe Japanese encephalitis complicated with hashimoto\u2019s thyroiditis and Guillain-Barr\u00e9 syndrome with protein a immunoadsorption: A case report","volume":"12","author":"Zang","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1083839\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:28:08Z","timestamp":1671622088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1083839\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":18,"alternative-id":["10.3389\/fcimb.2022.1083839"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.1083839","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"article-number":"1083839"}}